1033 related articles for article (PubMed ID: 26445379)
1. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
[TBL] [Abstract][Full Text] [Related]
2. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
3. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
Salamon J; Mautner VF; Adam G; Derlin T
Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
[TBL] [Abstract][Full Text] [Related]
4. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
5. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
6. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
7. [Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1].
Bensaid B; Giammarile F; Mognetti T; Galoisy-Guibal L; Pinson S; Drouet A; Combemale P
Ann Dermatol Venereol; 2007 Oct; 134(10 Pt 1):735-41. PubMed ID: 17978710
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
9. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
10. Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
Ziadi A; Saliba I
Auris Nasus Larynx; 2010 Oct; 37(5):539-45. PubMed ID: 20399579
[TBL] [Abstract][Full Text] [Related]
11. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
13. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
[TBL] [Abstract][Full Text] [Related]
15. Radiological findings of malignant peripheral nerve sheath tumor: reports of six cases and review of literature.
Yu YH; Wu JT; Ye J; Chen MX
World J Surg Oncol; 2016 May; 14():142. PubMed ID: 27159980
[TBL] [Abstract][Full Text] [Related]
16. Value of PET in the assessment of patients with neurofibromatosis type 1.
Bredella MA; Torriani M; Hornicek F; Ouellette HA; Plamer WE; Williams Z; Fischman AJ; Plotkin SR
AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
18. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
Uthoff J; De Stefano FA; Panzer K; Darbro BW; Sato TS; Khanna R; Quelle DE; Meyerholz DK; Weimer J; Sieren JC
J Neuroradiol; 2019 May; 46(3):179-185. PubMed ID: 29958847
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
[TBL] [Abstract][Full Text] [Related]
20. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
